ThermoGenesis Holdings, Inc. (NASDAQ:THMO) Sees Significant Drop in Short Interest

ThermoGenesis Holdings, Inc. (NASDAQ:THMO) was the recipient of a significant drop in short interest during the month of August. As of August 31st, there was short interest totalling 400 shares, a drop of 93.0% from the August 15th total of 5,700 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average daily volume of 71,200 shares, the days-to-cover ratio is currently 0.0 days.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of THMO. Virtu Financial LLC acquired a new position in shares of ThermoGenesis during the second quarter valued at $52,000. Renaissance Technologies LLC increased its holdings in shares of ThermoGenesis by 306.3% during the third quarter. Renaissance Technologies LLC now owns 156,000 shares of the company’s stock valued at $39,000 after purchasing an additional 117,600 shares during the period. Raymond James & Associates acquired a new position in shares of ThermoGenesis during the first quarter valued at $66,000. Two Sigma Investments LP acquired a new position in shares of ThermoGenesis during the first quarter valued at $40,000. Finally, Two Sigma Securities LLC acquired a new position in shares of ThermoGenesis during the first quarter valued at $37,000. 4.71% of the stock is owned by institutional investors and hedge funds.

ThermoGenesis Price Performance

Shares of NASDAQ THMO opened at $1.18 on Friday. ThermoGenesis has a 1-year low of $1.03 and a 1-year high of $14.40. The business’s fifty day moving average price is $1.28 and its two-hundred day moving average price is $1.84.

ThermoGenesis (NASDAQ:THMO) last issued its earnings results on Thursday, August 10th. The company reported ($0.91) earnings per share for the quarter, missing the consensus estimate of $0.01 by ($0.92). ThermoGenesis had a negative return on equity of 365.72% and a negative net margin of 145.48%. The company had revenue of $2.27 million during the quarter, compared to analyst estimates of $4.57 million. As a group, equities research analysts anticipate that ThermoGenesis will post -3.26 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $5.00 price objective on shares of ThermoGenesis in a research note on Friday, August 11th.

About ThermoGenesis

ThermoGenesis Holdings, Inc develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (CAR-T) and other cell-based therapies. It markets a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market.